Safety Shot, Inc. has addressed several comments from the Securities and Exchange Commission (SEC) regarding its Post-Effective Amendment No. 4 on Form S-1, initially filed on January 12, 2024. The SEC's comments, dated January 19, 2024, prompted revisions to the company's Registration Statement, particularly concerning the company's branding, liquidity, sales, and product development disclosures. Safety Shot clarified its branding, stating that 'Safety Shot Beverage' refers to the product, while 'Safety Shot' refers to the company itself. The company also outlined its limited contractual commitments, consisting mainly of salaries, rent, and clinical testing expenses, and its plans to use proceeds from product sales to fund inventory needs. Safety Shot revised disclosures related to declining sales in CBD products due to regulatory changes...Show More

Safety Shot, Inc. has addressed several comments from the Securities and Exchange Commission (SEC) regarding its Post-Effective Amendment No. 4 on Form S-1, initially filed on January 12, 2024. The SEC's comments, dated January 19, 2024, prompted revisions to the company's Registration Statement, particularly concerning the company's branding, liquidity, sales, and product development disclosures. Safety Shot clarified its branding, stating that 'Safety Shot Beverage' refers to the product, while 'Safety Shot' refers to the company itself. The company also outlined its limited contractual commitments, consisting mainly of salaries, rent, and clinical testing expenses, and its plans to use proceeds from product sales to fund inventory needs. Safety Shot revised disclosures related to declining sales in CBD products due to regulatory changes and wrote off its remaining CBD inventory. The company emphasized that future revenues would primarily come from the Safety Shot Beverage and licensing of other products. Additionally, Safety Shot updated its product development status, including regulatory approvals and plans for filing an IND application with the FDA for SS-100, and clarified the significance of Institutional Review Board approval for human trials. The company's counsel, Arthur Marcus, is available for further inquiries.